| Hepatitis E virus ORF2 inhibits RIG-I mediated interferon response S Hingane, N Joshi, M Surjit, CT Ranjith-Kumar Frontiers in microbiology 11, 656, 2020 | 26 | 2020 |
| A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound A Madhvi, S Hingane, R Srivastav, N Joshi, C Subramani, R Muthumohan, ... Scientific Reports 7 (1), 5816, 2017 | 25 | 2017 |
| Plasmodium palmitoylation machinery engineered in E. coli for high‐throughput screening of palmitoyl acyl‐transferase inhibitors P Yadav, R Ayana, S Garg, R Jain, R Sah, N Joshi, S Pati, S Singh FEBS Open Bio 9 (2), 248-264, 2019 | 17 | 2019 |
| Interaction of Plasmodium falciparum apicortin with α- and β-tubulin is critical for parasite growth and survival M Chakrabarti, N Joshi, G Kumari, P Singh, R Shoaib, A Munjal, V Kumar, ... Scientific Reports 11 (1), 4688, 2021 | 14 | 2021 |
| Pathogen induced subversion of NAD+ metabolism mediating host cell death: a target for development of chemotherapeutics A Chaurasiya, S Garg, A Khanna, C Narayana, VP Dwivedi, N Joshi, ... Cell Death Discovery 7 (1), 10, 2021 | 10 | 2021 |
| A De novo Peptide from a High Throughput Peptide Library Blocks Myosin A -MTIP Complex Formation in Plasmodium falciparum Z Anam, N Joshi, S Gupta, P Yadav, A Chaurasiya, AK Kahlon, S Kaushik, ... International Journal of Molecular Sciences 21 (17), 6158, 2020 | 10 | 2020 |
| Metalloprotease Gp63-targeting novel glycoside exhibits potential antileishmanial activity A Chakrabarti, C Narayana, N Joshi, S Garg, LC Garg, A Ranganathan, ... Frontiers in cellular and infection microbiology 12, 803048, 2022 | 6 | 2022 |
| Highly potent anti-malarial activity of benzopyrano (4, 3-b) benzopyran derivatives and in silico interaction analysis with putative target Plasmodium falciparum lactate … N Joshi, R Hada, S Gupta, J Khan, J Dobrowolski, PK Dhar, N Kumar, ... Journal of Biomolecular Structure and Dynamics 40 (11), 5159-5174, 2022 | 5 | 2022 |
| Targeting Artemisinin-Resistant Malaria by Repurposing the Anti-Hepatitis C Virus Drug Alisporivir A Chaurasiya, G Kumari, S Garg, R Shoaib, Z Anam, N Joshi, J Kumari, ... Antimicrobial Agents and Chemotherapy 66 (12), e00392-22, 2022 | 4 | 2022 |
| Cytoprotective autophagy as a pro-survival strategy in ART-resistant malaria parasites D Kannan, N Joshi, S Gupta, S Pati, S Bhattacharjee, G Langsley, S Singh Cell Death Discovery 9 (1), 160, 2023 | 2 | 2023 |
| Antimalarial and Plasmodium falciparum serpentine receptor 12 targeting effect of a purinergic receptor antagonist FDA approved drug S Gupta, N Joshi, M Saini, S Singh bioRxiv, 2020.12. 16.423179, 2020 | 2 | 2020 |
| POSSIBLE LINK BETWEEN PERIODONTAL DISEASE AND CHRONIC PROSTATITIS: PD20-05 J Estemalik, N Bissada, N Joshi, C Demko, E Shankar, D Bodner, S Gupta Journal of Urology 195 (4), e452, 2016 | 2 | 2016 |
| Targeting the artemisinin resistant malaria by repositioning of the anti-Hepatitis C Virus drug Alisporivir A Chaurasiya, S Garg, Z Anam, G Kumari, N Joshi, J Kumari, J Singhal, ... bioRxiv, 2021.01. 08.426017, 2021 | 1 | 2021 |
| Antimalarial and Plasmodium falciparum serpentine receptor 12 targeting effect of FDA approved purinergic receptor antagonist S Gupta, M Saini, N Joshi, S Shafi, AK Najmi, S Singh Journal of Biomolecular Structure and Dynamics 41 (19), 9462-9475, 2023 | | 2023 |
| Antimalarial andPlasmodium falciparumserpentine receptor 12 targeting effect of a purinergic receptor antagonist FDA approved drug S Gupta, N Joshi, M Saini, S Singh | | 2020 |
| When is immune thrombocytopenia not immune thrombocytopenia? Using high-throughput sequencing to distinguish patients with inherited thrombocytopenia and diseases of immune … N Joshi, M Gallanagh, H Lango-Allen, K Downes, I Simeoni, N Cooper BRITISH JOURNAL OF HAEMATOLOGY 189, 43-44, 2020 | | 2020 |
| Integrative in vitro and in silico approaches for understanding host pathogen interactions in human malaria parasite for drug discovery N Joshi Greater Noida, 0 | | |
